Drugs / ROPSACITINIB
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04591262 | Nov 2020 → Jan 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04134715 | Oct 2019 → Jan 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03210961 | Jul 2017 → Jan 2019 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04209556 | Sep 2020 → Oct 2023 | ulcerative colitis | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT04092452 | Dec 2019 → Jan 2022 | hidradenitis suppurativa | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT03895372 | Jun 2019 → May 2020 | psoriasis | Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROPSACITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4459585 ↗ |
| Known as | PF-06826647 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04209556 ↗ |
| Known as | PF-647 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4459585 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase TYK2 inhibitor” CHEMBL4459585 ↗1“the TYK2 inhibitor PF-06826647” PMID 38279383 ↗ Dec 2020 |
| Modality | Small molecule | — CHEMBL4459585 ↗ |
| Route | Oral | “assessed once daily oral dosing of PF-06826647 in participants with plaque psoriasis” PMID 38279383 ↗ Dec 2020 |
| Target | TYK2 | “Tyrosine-protein kinase TYK2 inhibitor” CHEMBL4459585 ↗ |